FDA-Approved Therapies and Multidisciplinary Care Extend Survival in ALS

Amyotrophic lateral sclerosis remains one of the most challenging neurodegenerative disorders in clinical practice, characterized by the relentless degeneration of both upper and lower motor neurons [1]. Because the biological triggers of the disease are only partially understood, clinicians face a complex diagnostic process and historically limited therapeutic options [2]. Current management strategies emphasize evidence-based guidelines to address the progressive muscle atrophy and respiratory failure that define the disease course [3]. While the search for definitive biomarkers to monitor progression continues, clinical focus has shifted toward refining patient stratification to optimize the use of available disease-modifying agents [4]. A recent clinical review synthesizes the current standards for diagnosis, genetic testing, and the integration of newly approved pharmacological interventions, offering physicians an updated roadmap for managing this fatal condition.